[Development of novel epigenetic molecular-targeting agents].

Abstract excerpt

Cancer is known to be a genetic disease, which is caused by abnormalities of oncogenes and/or tumor-suppressor genes. Genetic abnormalities include mutation, deletion or amplification of DNA sequences. Based on the findings of the genetic abnormalities in malignant tumors, many molecular-targeting agents, e.g. Bcr-Abl kinase inhibitors and EGFR kinase inhibitors, have been developed and approved. In addition to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acetylation
• Share to DNA (Cytosine-5-)-Methyltransferases
• Share to Drug Discovery